The FDA says that some companies are selling blood plasma from young people (allegedly) and saying it wards off diseases associated with old age.
“We’re alerting consumers and health-care providers that treatments using plasma from young donors have not gone through the rigorous testing that the FDA normally requires,” FDA Commissioner Scott Gottlieb and Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement.
Blood plasma is loaded with protein and has been used in trauma units and emergency departments to help stem bleeding.
“Plasma is not FDA-recognized or approved to treat conditions such as normal aging or memory loss, or other diseases like Alzheimer’s or Parkinson’s disease,” Gottlieb and Marks said in their statement. “Moreover, reports we’re seeing indicate that the dosing of these infusions can involve administration of large volumes of plasma that can be associated with significant risks including infectious, allergic, respiratory and cardiovascular risks, among others.”
CNN reports that a company called Ambrosia that allegedly sold blood plasma issued a statement that it is following the FDA’s directive. “In compliance with the FDA announcement issued February 19, 2019, we have ceased patient treatments,” the company said on its website.